Abstract
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone loss related to androgen-deprivation therapy (ADT) and/or patients who develop bone metastases. The number of treatment options for advanced prostate cancer that combine ADT with docetaxel, new hormonal agents and/or radiotherapy has increased substantially in recent years. Bisphosphonates and other bone targeted agents such as denosumab have shown an improvement in bone mineral density and are suited for patients with treatment-related osteoporosis and/or bone metastases with an increased risk of skeletal-related events (SREs). In this context, the aim of this review is to analyse key aspects of bone health and therapies that can prevent the occurrence of SREs throughout the clinical course of prostate cancer, and how to combine them with new available treatments in this setting.
Highlights
Prostate cancer (PCa) is the most frequent solid tumor in males and androgen-deprivation therapy (ADT) plays an important role in its treatment, both as part of definitive therapy and in advanced or metastatic stages, where it continues to be a first line treatment
Osteopenia occurs in up to 85% of cases and osteoporosis ranges, according to different studies, between 9–53% [2,3]. The magnitude of this osteopenia is associated with the duration of androgen suppression, several studies show that the most important loss in bone mineral density (BMD)—up to 10% depending on the location— occurs during the first year of ADT [1,3,4]
The comprehensive management of advanced PCa must include an early evaluation of bone health
Summary
Prostate cancer (PCa) is the most frequent solid tumor in males and androgen-deprivation therapy (ADT) plays an important role in its treatment, both as part of definitive therapy and in advanced or metastatic stages, where it continues to be a first line treatment. Osteopenia occurs in up to 85% of cases and osteoporosis ranges, according to different studies, between 9–53% [2,3] The magnitude of this osteopenia is associated with the duration of androgen suppression (among other factors), several studies show that the most important loss in bone mineral density (BMD)—up to 10% depending on the location— occurs during the first year of ADT [1,3,4]. Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations These lesions frequently generate pain and skeletalrelated events (SREs) that can be caused by secondary osteopenia due to prolonged ADT use or by pathologic fractures secondary to a bone metastasis. The aim of this review is to analyse the correct assessment of bone health, as well as the main targeted treatments and their association with specific oncological treatments for PCa patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
